• Speakers

  • Confirmed speakers

    - Andrea Ablasser (CH)
    - Charles Bangham (UK)
    - Yenan Bryceson (SE)
    - Andrea Cerutti (USA)
    - Adelheid Cerwenka (DE)
    - Yannick Crow (UK)
    - Marc Dalod (FR)
    - Andreas Diefenbach (DE)
    - Jolanda de Vries (NL)
    - Johanna Joyce (USA)
    - Simon Fillatreau (UK)
    - Veit Hornung (DE)
    - Antonio Lanzavecchia (CH)
    - Nicolas Manel (FR)
    - Antoine Marçais (FR)
    - Julien Marie (FR)
    - Claudia Mauri (UK)
    - Boris Reizis (USA)
    - Claude-Agnès Reynaud (FR)
    - Alexander Rudensky (USA)
    - Daniel B. Stetson (USA)
    - Marc Veldhoen (UK)

  • Pr Andrea Ablasser, Assistant Professor, Global Health Institute, EPFL Lausanne Switzerland

    The goals of Pr Ablasser research is to understand how the cells of our immune system detect the presence of pathogens and to dissect the fundamental mechanisms that provide host defense. Her research focuses on the identification of receptors responsible for the intracellular recognition of pathogen-derived molecular patterns and on the elucidation of the consecutive signaling events. She also aims towards a better understanding of the physiological functions of these pathways during pathogen infection.

    Pr Charles Bangham, Imperial College London, UK

    Charles Bangham is Professor of Immunology and Head of the Division of Infectious Diseases in Imperial College London. His research interests are in the immunology and virology of persistent viral infections, particularly the human leukaemia virus HTLV-1.

    Dr Yenan Bryceson, Karolinska Institutet, Stockholm, Sweden

    Dr Bryceson a principal investigator within a Center for Hematology and Regenerative Medicine. He studies the molecular basis for primary immunodeficiencies impairing cytotoxic lymphocyte differentiation and function.

    Dr. Andrea Cerutti, Professor at the Department of Medicine of Mount Sinai School of Medicine.

    Pr Cerutti leads a research group in the Immunology Institute of the Icahn School of Medicine at Mount Sinai. He studies the regulation of systemic and mucosal antibody production and diversification in health and disease states, including HIV infection.

    Dr Adelheid Cerwenka, DKFZ, Heidelberg, Germany

    Dr Cerwenka is the head of the Innate Immunity laboratory. She investigates Natural Killer (NK) cells and myeloid cell subsets in cancer with the goal to improve therapeutic anti-tumor strategies.

    Professor Yanick Crow – Institut Imagine, Paris, France and University of Manchester, UK

    Professor Crow leads a research group focusing on monogenic phenotypes associated with an upregulation of type I interferon – the so-called type I interferonopathies.

    Dr Marc Dalod, Centre d’Immunologie de Marseille-Luminy, Marseille, France

    Dr Dalod is heading the team “Dendritic cells and antiviral defense”. Currently, he is also the CIML deputy director (2015-2017). His investigations are mainly focused on understanding which subsets of dendritic cells (DC) promote protective antiviral or anti-tumoral immunity, and how, during natural history of diseases or upon different types of therapies. In this frame, he is also investigating the molecular bases of the functional polarization of DC subsets towards immunity versus tolerance.

    Professor Andreas Diefenbach, Research Centre for Immunology, University of Mainz Medical Centre, Germany.

    Prof Diefenbach is the coordinator of the Research Centre for Immunology and chair of the Microbiology Department at the University of Mainz Medical Centre. His research is focussed on understanding the innate immune system and, in particular, the biology and development of innate lymphoid cells.

    Jolanda de Vries, Department of Tumor Immunology, Institute for Molecular Life Sciences, RADBOUD UMC, Netherlands

    Jolanda de Vries is Professor at the Department of Tumor Immunology at the Nijmegen Centre for Molecular Life Sciences. She was one of the pioneers to translate dendritic cell biology into potential clinical applications. The first clinical phase I/II studies in which patients were vaccinated with DCs loaded with tumor-specific peptides were initiated in 1997. Her primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC. For example, in-vivo imaging of ex-vivo labeled cells using MRI (Nature Biotechnology 2005). New opportunities for other cell-types (e.g. subsets of DCs) are now being developed. She recently completed the first plasmacytoid DC vaccination trial.

    Dr Simon Fillatreau, INSERM U1151/CNRS UMR8253 Institut Necker-Enfants Malades (INEM), Paris, France.

    Dr Simon Fillatreau heads the team « Normal and Pathological Immunity » at INEM. His main research interest lies in understanding the regulatory functions of B cells and plasma cells in autoimmune inflammatory diseases and bacterial infections. His present research focuses on discovery of novel antibody-independent functions of plasma cells and on their manipulation for suppression of unwanted immunity. 

    Pr Veit Hornung, Gene Center and Department of Biochemistry, Ludwig-Maximilians-University Munich, Germany

    His research projects aim at understanding what mechanisms are employed by the innate immune system to distinguish self from non-self or harmless from dangerous, respectively. Central to this complex task is a repertoire of pattern recognition receptors (PRRs) that have evolved to detect the presence of microorganisms. The ligands or targets of these PRRs are commonly referred to as microbe-associated molecular patterns (MAMPs). At the same time, some PRRs can also be triggered by endogenous substances that are formed or released during cell stress, perturbation of tissue homeostasis or metabolic imbalance. In analogy to the MAMP terminology, these signals are commonly referred to as damage-associated molecular patterns (DAMPs). Most of our research efforts focus on the interplay of the PRR system with its ligands. To this effect, (i) we are trying to decipher relevant MAMP or DAMP molecules during infection or sterile inflammation, (ii) we aim at the identification of novel PRRs, signaling cascades and their functional roles, and (iii) we develop strategies to manipulate this interface for therapeutic application

    Dr Johanna Joyce, Ludwig Institute for Cancer Research, University of Lausanne, Switzerland

    Dr. Joyce was Member in the Cancer Biology Program at Memorial Sloan Kettering Cancer Center (MSKCC) and a Professor of Cell Biology and Genentics at Weill Cornell University Graduate School of Medical Sciences. She received her doctorate in Biology from the University of Cambridge, England in 1999 and completed her postdoctoral training in Dr. Douglas Hanahan's lab at University of California, San Francisco. She joined MSKCC in December 2004 and was named to a Geoffrey Beene Junior Faculty Chair in 2007. She recently move from New York to the Ludwig Institute for Cancer Research, University of Lausanne, in Switzerland. Her research interests are to understand the mechanisms by which stromal cells in the tumor microenvironment regulate cancer development, metastasis, and response to therapy.

    Antonio Lanzavecchia, Institute for Research in Biomedicine in Bellinzona, Switzerland

    From 1983 to 1999 he was a member of the Basel Institute for Immunology and since 1999 he is the founding director of the IRB in Bellinzona. Dr. Lanzavecchia has published more than 270 papers. His research has covered several aspects of human immunology: antigen processing and presentation, dendritic cell biology, lymphocyte activation and traffic, T and B cell memory. Recently he developed a method for the efficient isolation of human monoclonal antibodies from memory B cells, which has been successfully applied to infectious diseases such as SARSCoV, H5N1, HCMV, Dengue, Malaria and HIV-1. He further address fundamental issues with regard to the cellular basis of immunological memory, and the relationship between infection and autoimmunity.

    Dr Nicolas MANEL, Institut Curie, Paris

    Dr Manel is heading the team “human innate immunity”. His research is focused on understanding the innate immune response against HIV. The projects developed in the lab include the study of viral determinants of sensing in HIV, of the cellular mechanisms of sensing and of the impact of the innate sensing and dendritic cells on adaptive immunity. Notably, his lab recently uncovered how the host factor Cyclophilin A intersects with the reverse transcription and nuclear import of HIV genome.

    Dr Claudia Mauri, Centre for Rheumatology Research Division of Medicine University College, London, UK.

    Claudia Mauri is Professor of Immunology and Vice-Dean International Faculty of Medical Science at University College in London. Her main research interest lies in understanding the mechanisms driving autoimmunity with a particular interest in understanding the function of regulatory B cells in patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis and the influence of gut bacteria in their development.

    Dr Antoine Marçais, CIRI, Lyon, France

    Dr Marçais is a researcher at the CIRI (Lyon, France) in the « Innate immunity in infectious and autoimmune diseases » group headed by Dr Walzer. His research is focused on understanding the signalling pathways controlling NK cell development and function with a particular emphasis on the role of the mTOR kinase in these processes. He has recently described the role of mTOR during the development of NK cells and demonstrated a role for this kinase as an integrator of pro- and anti-inflammatory signals affecting the NK cell population.

    Julien MARIE, Cancer Research Centre of Lyon, France

    Dr Marie is settled at the department of immunology, virology and inflammation of the CRCL, Lyon France. The research of the Marie lab is focused on the regulation of the immune responses and particularly on the action of the Transforming Growth Factor beta (TGF-beta) on the T cell-response. Over the last decade, the Marie lab demonstrated the importance of the TGF-beta on the control of autoimmunity, infections and immune responses in the cancer biology.

    Boris Reizis, Ph.D., Professor in Pathology and Medicine Department, New York University Langone Medical Center

    Boris Reizis did his thesis research in immunology with Irun R. Cohen at the Weizmann Institute, and trained as a postdoc with Philip Leder at Harvard Medical School. In late 2003 he started his lab at Columbia University Medical Center, where he became a tenured Associate Professor in 2010 and a Professor in 2014. In the summer of 2015 he joined New York University Langone Medical Center as a Professor in the departments of Pathology and Medicine.

    Dr Claude Agnès Reynaud, INSERM U1151/CNRS UMR8253 Institut Necker-Enfants Malades (INEM), Paris, France.

    Dr Reynaud is co-director of the team “Development of the Immune System” at INEM. She has a long-lasting interest in the molecular and cellular mechanisms involved in the development and diversification of the B cell repertoire. She made significant contributions to the field of B cell memory. Her present research is focused on investigating the discrepancies observed between mouse models of immune responses and observations performed in humans.

    Prof Alexander Y. Rudensky, Memorial Sloan Kettering Institute Cancer Center, New York, USA

    Prof Rudensky is the chair of the Immunology program of the MSK and director of the Ludwig Center for Cancer Immunotherapy. His investigations are mainly focused on immunological tolerance and the differentiation and function of T cells.

    Pr Daniel B Stetson, Associate Professor in immunology Departement of immunology, University of Washington, USA

    All organisms have viral pathogens, and an ancient and fundamental mechanism for detecting viral infection makes use of sensors that recognize viral nucleic acids. In vertebrates, these sensors coordinate an inducible antiviral response by activating the production of type I interferons (IFNs).
    Research in the Stetson lab focuses on mechanisms by which cells detect and respond to viral infection.
    They are particularly interested in a recently described pathway that detects cytosolic DNA within mammalian cells. One goal of his research is to define the specific signaling cascades of the ISD pathway and, more importantly, to determine why they are different from those activated by viral RNA. Another is to understand the biological relevance of the ISD pathway and its connections to Toll-like receptor mediated nucleic acid detection.

    Marc Veldhoen, Cambridge, UK

    Dr Veldhoen studies the role that cells of the immune system play at the initiation, modulation and resolution of immune responses at epithelial barrier sites. These studies provide insights into the mechanisms that control the maintenance of a resident population of micro-organisms, promoting healthy living, and the prevention of undesirable immune responses that may result in chronic infections, allergies, autoimmunity and an increased risk of cancer.

  • Registration & Accommodation
    39 chemin du vieux chêne
    38240 Meylan
    Tel: +33 825 595 525 (0,15€/min*)
    Fax: +33 4 38 38 18 19
    Information desk
    monday to friday from 2pm to 5pm
    Immune Responses In Cancer and Infection
    69000 Lyon
    (*) Prices starting from fixed line incumbent, a surcharge may be applied by operators, counting the second after the first 45 seconds.

    According to France's Personal Data Privacy Act in effect since June 2004, you may send a request in writing to INSIGHT OUTSIDE 39 chemin du vieux chêne, 38240 Meylan / France, or by email webmaster@insight-outside.fr to access your file in order to consult, modify and/or delete your personal information.

    © 2005 - 2020 Insight Outside